Navigating the Evolving Pharmaceutical Landscape of FDA Regulation, Patent Strategy and Antitrust Risk: Key Takeaways ...
Key Points Policy priorities under current leadership at the FDA are focused on reforming the Investigational New Drug application process and encouragement of innovation in rare diseases. The USPTO is seeing lower institution rates for inter partes review …